At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 428 enrolled
Drug / intervention
Plecanatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
In Brief
A Phase 2 clinical trial evaluating Plecanatide and Placebo for Irritable Bowel Syndrome Characterized by Constipation. Completed, enrolled 428 participants across 99 sites.
Detailed Summary
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionApr 2014
Study CompletionOct 2014
TodayJul 2026
First PostedNov 6, 2012
Enrollment StartNov 1, 2012
Primary CompletionApr 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.7 years ago
Interventions
Plecanatidedrug
Placebodrug